
The toxic effects and tissue zzso of both zzso and zzso zzso zzso previously shown to vary similarly according to dosing time in zzso A zzso infusion of zzso resulted in fewer side effects and allowed administration of higher doses at 16 hours than at 4 hours in patients with zzso We hypothesized that the continuous zzso infusion of zzso for 5 days would be less toxic and would deliver a higher dose to the patient if the drug were infused at a zzso zzso rate zzso at 16 zzso schedule zzso rather than at a constant rate zzso zzso We tested this hypothesis in a zzso phase I zzso We escalated the dose of zzso to the patient by 25 zzso per zzso Courses were repeated every 3 zzso An zzso zzso zzso pump was used for the zzso zzso was zzso for 94 courses in 23 patients (12 patients with breast zzso nine with zzso zzso and two with zzso The zzso of zzso of World Health Organization grades zzso and the zzso of zzso zzso were 10 or more times higher zzso less than zzso with schedule A than with schedule zzso In addition, vomiting was zzso higher zzso zzso zzso with schedule A than with schedule zzso Furthermore, with schedule B, the mean dose of zzso zzso less than zzso and its maximum tolerated dose zzso zzso zzso could be increased by zzso over those doses with schedule zzso An objective response was achieved in two of the 12 patients with previously treated breast zzso We recommend that the dose of zzso for phase II trials be 175 zzso delivered according to the zzso zzso zzso 

